This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
Malignant Meningioma
Information about Malignant Meningioma: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of Malignant Meningioma
Most recent studies have shown that Malignant Meningioma shares some biological mechanisms with astrocytoma, benign-meningioma, brain-neoplasms, cell-invasion, edema, glioblastoma, glioma, intracranial-meningioma, intracranial-neoplasm, malignant-neoplasms, malignant-paraganglionic-neoplasm, meningeal-neoplasms, meningioma, neoplasm-invasiveness, neoplasm-metastasis, neoplasm-recurrence-local, neoplasms, nervousness, recurrence-(disease-attribute).
Among the many pathways, these few ones have gauged particular interests from scientists studying Malignant Meningioma, and have been seen in publications frequently: Angiogenesis, Cell Cycle, Cell Cycle Arrest, Cell Death, Cell Growth, Cell Proliferation, Coagulation, Dedifferentiation, Immune Response, Invasive Growth, Localization, Methylation, Mitosis, Pathogenesis, Reverse Transcription, S Phase, Secretion, Senescence, Translation
Quite a number of genes have been found to play important roles in Malignant Meningioma, such as AKT1, BCL2, CDKN2A, CDKN2B, CSF2, CTSB, GFAP, LAMC2, MMP9, MUC1, NF2, NLRP5, PCNA, PGR, PLAU, PLAUR, TP53, VIM. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.